Correlation Between Fate Therapeutics and BriaCell Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Fate Therapeutics and BriaCell Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fate Therapeutics and BriaCell Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Fate Therapeutics and BriaCell Therapeutics Corp, you can compare the effects of market volatilities on Fate Therapeutics and BriaCell Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fate Therapeutics with a short position of BriaCell Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fate Therapeutics and BriaCell Therapeutics.

Diversification Opportunities for Fate Therapeutics and BriaCell Therapeutics

0.04
  Correlation Coefficient

Significant diversification

The 3 months correlation between Fate and BriaCell is 0.04. Overlapping area represents the amount of risk that can be diversified away by holding Fate Therapeutics and BriaCell Therapeutics Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BriaCell Therapeutics and Fate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fate Therapeutics are associated (or correlated) with BriaCell Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BriaCell Therapeutics has no effect on the direction of Fate Therapeutics i.e., Fate Therapeutics and BriaCell Therapeutics go up and down completely randomly.

Pair Corralation between Fate Therapeutics and BriaCell Therapeutics

Given the investment horizon of 90 days Fate Therapeutics is expected to under-perform the BriaCell Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Fate Therapeutics is 1.75 times less risky than BriaCell Therapeutics. The stock trades about -0.17 of its potential returns per unit of risk. The BriaCell Therapeutics Corp is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  34.00  in BriaCell Therapeutics Corp on September 26, 2024 and sell it today you would lose (10.00) from holding BriaCell Therapeutics Corp or give up 29.41% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Fate Therapeutics  vs.  BriaCell Therapeutics Corp

 Performance 
       Timeline  
Fate Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Fate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
BriaCell Therapeutics 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in BriaCell Therapeutics Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, BriaCell Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Fate Therapeutics and BriaCell Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Fate Therapeutics and BriaCell Therapeutics

The main advantage of trading using opposite Fate Therapeutics and BriaCell Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fate Therapeutics position performs unexpectedly, BriaCell Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BriaCell Therapeutics will offset losses from the drop in BriaCell Therapeutics' long position.
The idea behind Fate Therapeutics and BriaCell Therapeutics Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

Share Portfolio
Track or share privately all of your investments from the convenience of any device
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Fundamental Analysis
View fundamental data based on most recent published financial statements